Charles River Laboratories Intl. Inc to Post Q1 2018 Earnings of $1.24 Per Share, KeyCorp Forecasts (CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – Research analysts at KeyCorp issued their Q1 2018 earnings per share (EPS) estimates for Charles River Laboratories Intl. in a note issued to investors on Tuesday. KeyCorp analyst D. Hooker expects that the medical research company will earn $1.24 per share for the quarter. KeyCorp also issued estimates for Charles River Laboratories Intl.’s Q2 2018 earnings at $1.43 EPS, Q3 2018 earnings at $1.38 EPS, Q4 2018 earnings at $1.44 EPS, FY2018 earnings at $5.49 EPS and FY2019 earnings at $6.09 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.26 by $0.14. Charles River Laboratories Intl. had a net margin of 6.64% and a return on equity of 26.14%. The company had revenue of $478.50 million during the quarter, compared to analysts’ expectations of $475.02 million. During the same quarter in the previous year, the company earned $1.21 earnings per share. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis.

A number of other research analysts have also recently weighed in on CRL. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a report on Tuesday, October 24th. Bank of America cut their price objective on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a report on Friday, November 10th. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Robert W. Baird set a $117.00 price objective on shares of Charles River Laboratories Intl. and gave the company a “buy” rating in a report on Monday, November 13th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $113.00 price objective on shares of Charles River Laboratories Intl. in a report on Friday, November 17th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $114.85.

Charles River Laboratories Intl. (NYSE:CRL) opened at $110.31 on Thursday. Charles River Laboratories Intl. has a fifty-two week low of $86.25 and a fifty-two week high of $119.05. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.62. The firm has a market cap of $5,106.20, a price-to-earnings ratio of 43.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.74.

In other news, Director Online Communications Bdirect sold 131,000 shares of the business’s stock in a transaction dated Thursday, January 18th. The shares were sold at an average price of $0.29, for a total transaction of $37,990.00. Also, Chairman James C. Foster sold 4,967 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.44, for a total transaction of $543,588.48. Following the sale, the chairman now directly owns 329,928 shares of the company’s stock, valued at approximately $36,107,320.32. The disclosure for this sale can be found here. Insiders have sold 195,673 shares of company stock valued at $2,644,046 in the last three months. Corporate insiders own 2.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in Charles River Laboratories Intl. by 0.8% during the 4th quarter. BlackRock Inc. now owns 4,034,318 shares of the medical research company’s stock valued at $441,557,000 after acquiring an additional 31,676 shares in the last quarter. Renaissance Technologies LLC grew its stake in Charles River Laboratories Intl. by 4.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,398,700 shares of the medical research company’s stock valued at $153,088,000 after acquiring an additional 58,991 shares in the last quarter. State Street Corp grew its stake in Charles River Laboratories Intl. by 2.3% during the 2nd quarter. State Street Corp now owns 1,268,308 shares of the medical research company’s stock valued at $128,288,000 after acquiring an additional 28,365 shares in the last quarter. Mackenzie Financial Corp grew its stake in Charles River Laboratories Intl. by 15.3% during the 4th quarter. Mackenzie Financial Corp now owns 1,071,178 shares of the medical research company’s stock valued at $117,240,000 after acquiring an additional 142,382 shares in the last quarter. Finally, TimesSquare Capital Management LLC grew its stake in Charles River Laboratories Intl. by 181.1% during the 4th quarter. TimesSquare Capital Management LLC now owns 915,600 shares of the medical research company’s stock valued at $100,212,000 after acquiring an additional 589,900 shares in the last quarter. 97.13% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories Intl. Inc to Post Q1 2018 Earnings of $1.24 Per Share, KeyCorp Forecasts (CRL)” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://weekherald.com/2018/02/15/charles-river-laboratories-intl-inc-to-post-q1-2018-earnings-of-1-24-per-share-keycorp-forecasts-crl.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply